The Effect of Semaglutide on Pituitary Function

NCT04865744 on ClinicalTrials.gov · last registry update 2023-02-22

A small phase 4 — 10 participants, against a typical 75. The sponsor logged completion for 23 September 2021. Primary outcome, as filed: Growth hormone peak.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Tartu
Sponsor type: Other
Enrollment: 10
Started: 2021-05-19
Primary completion: 2021-09-23 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Growth hormone peak

Conditions studied

Healthy

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.